Educational Disclaimer: This case study is for educational and informational purposes only. It does not constitute medical advice, clinical guidance, or a substitute for professional psychiatric evaluation. All diagnostic criteria referenced are from the DSM-5-TR (APA, 2022). Clinicians should rely on their professional training, direct patient assessment, and current evidence-based guidelines when making diagnostic and treatment decisions.

Clinical Vignette

Patient: "Ms. V," 22-year-old college senior, presenting after she collapsed in class during a laughing episode and woke up on the floor.

Chief Concern: "I've been incredibly sleepy during the day since I was 15. I fall asleep in class, during conversations, even while eating. Last week in class, a friend made a joke, I laughed hard, and my legs gave out — I collapsed. It wasn't a seizure; I was fully conscious the entire time but couldn't move my legs."

History of Present Illness: Ms. V reports a 7-year history of excessive daytime sleepiness (EDS) with onset at age 15. Sleep attacks: irresistible urges to sleep occurring 3-5 times daily, lasting 10-20 minutes. She falls asleep in all settings: lectures, conversations, meals, and once while driving (minor accident). She sleeps 8-9 hours nightly but does NOT feel refreshed. Cataplexy: over the past 2 years, she has experienced sudden bilateral muscle weakness triggered by strong emotions (especially laughter): jaw slackening (jaw drops), knee buckling, and last week complete collapse. During cataplexy episodes, she is FULLY CONSCIOUS — she can hear and see but cannot move. Episodes last 30 seconds to 2 minutes. Sleep paralysis: upon waking, she occasionally cannot move for 1-2 minutes (occurs ~2x/month). Hypnagogic hallucinations: vivid, dream-like images at sleep onset (~1x/week) — sees figures in her room that she recognizes as 'not real.' Disrupted nocturnal sleep: despite EDS, her nighttime sleep is fragmented with multiple awakenings.

Medical History: No medical conditions. No medications. No substance use. Polysomnography: normal sleep architecture, no sleep apnea. MSLT: mean sleep latency 3 minutes (normal >8), 4/5 SOREMPs (sleep-onset REM periods). CSF orexin (hypocretin-1) level: undetectable (<110 pg/mL).

Mental Status Exam: Alert during interview but yawned repeatedly. Eyes heavy-lidded. Nearly fell asleep twice during 45-minute interview (caught herself). Cognition intact when awake. Mood 'frustrated — people think I'm lazy or not interested.' Affect appropriate. No depression. No psychotic symptoms.

Step 1: Narcolepsy Type 1 DSM-5-TR Criteria

Criterion A: Recurrent periods of irrepressible need to sleep, lapsing into sleep, or napping occurring within the same day, ≥3x/week for ≥3 months.

3-5 daily sleep attacks for 7 years. Falls asleep in class, conversations, meals. Far exceeds threshold. MET.

Criterion B: At least one of: (1) Cataplexy; (2) Hypocretin deficiency.

(1) Cataplexy PRESENT: bilateral muscle weakness triggered by laughter (jaw slacking, knee buckling, full collapse). Consciousness preserved. (2) CSF hypocretin-1 UNDETECTABLE (<110 pg/mL). Both present. MET — BOTH cataplexy AND hypocretin deficiency.

MSLT confirmation:

Mean sleep latency 3 minutes (<8 = pathological sleepiness). 4/5 SOREMPs (≥2 required). Consistent with narcolepsy. CONFIRMATORY.

Step 2: The Narcolepsy Tetrad

Feature Description Frequency in NT1 This Patient
1. EDS Irresistible daytime sleepiness with sleep attacks 100% (required) Present — 3-5 daily sleep attacks, 7 years
2. Cataplexy Sudden bilateral loss of muscle tone triggered by emotion, consciousness preserved ~70-80% Present — laughter-triggered collapse
3. Sleep paralysis Inability to move upon waking or falling asleep ~25-50% Present — 2x/month upon waking
4. Hypnagogic hallucinations Vivid dream intrusions at sleep-wake transitions ~30-60% Present — 1x/week, visual figures

Pathophysiology

Narcolepsy Type 1 results from loss of hypocretin (orexin)-producing neurons in the lateral hypothalamus. This loss eliminates the stabilization of the sleep-wake switch, causing intrusions of REM sleep phenomena (muscle atonia = cataplexy; dream imagery = hallucinations; REM paralysis = sleep paralysis) into wakefulness. Ms. V's undetectable CSF hypocretin confirms this mechanism.

Diagnostic Formulation

Diagnostic Conclusion

Narcolepsy Type 1, with Cataplexy (G47.411): All DSM-5-TR criteria met. EDS + cataplexy + hypocretin deficiency confirmed. MSLT confirmatory (MSL 3 min, 4 SOREMPs). Full tetrad present. Treatment: (1) EDS: modafinil or armodafinil (first-line wake-promoting agents); or sodium oxybate (treats both EDS and cataplexy). (2) Cataplexy: sodium oxybate (most effective for cataplexy), or venlafaxine/fluoxetine (REM-suppressing antidepressants reduce cataplexy). (3) Scheduled naps (strategic 15-20 minute naps to reduce sleep pressure). (4) Sleep hygiene optimization. (5) Driving safety assessment and counseling.

Teaching Points

  • Narcolepsy Type 1 is defined by excessive daytime sleepiness PLUS cataplexy or hypocretin deficiency. Narcolepsy Type 2 has EDS but NO cataplexy and normal hypocretin levels. This distinction is important because the pathophysiology differs: Type 1 involves loss of hypocretin neurons, while Type 2's mechanism is less understood.
  • Cataplexy is PATHOGNOMONIC for Narcolepsy Type 1. No other condition produces this symptom. Key features: bilateral muscle weakness (not unilateral), triggered by strong emotions (especially positive emotions like laughter), consciousness is PRESERVED throughout (the patient knows what is happening but cannot move), and duration is brief (seconds to minutes).
  • CSF hypocretin-1 (orexin-A) measurement is the definitive biomarker for Narcolepsy Type 1. Levels ≤110 pg/mL (or ≤1/3 of normal mean) are diagnostic. In Narcolepsy Type 1, levels are typically undetectable. This test is rarely needed when classic cataplexy is present but is valuable in ambiguous cases.
  • The MSLT (Multiple Sleep Latency Test) is the standard diagnostic sleep study for narcolepsy. Mean sleep latency <8 minutes indicates pathological sleepiness. ≥2 SOREMPs (sleep-onset REM periods) indicate abnormal REM regulation consistent with narcolepsy. Ms. V's MSL of 3 minutes and 4 SOREMPs are strongly positive.
  • Sodium oxybate (gamma-hydroxybutyrate/GHB) is the only medication that treats ALL narcolepsy symptoms (EDS, cataplexy, disturbed nocturnal sleep, and accessory symptoms). It is taken in divided doses at bedtime. Despite its controlled substance status (Schedule III), it is the most effective treatment for narcolepsy with cataplexy.